This study is an open-label, multi-center Phase II clinical study, aimed to evaluate the efficacy and safety of camrelizumab combined with famitinib malate and platinum-based chemotherapy in the treatment of recurrent/metastatic cervical cancer.
Female aged 18-75 years.
Histopathologically confirmed recurrent/metastatic cervical squamous cell carcinoma, adenocarcinoma or adenosquamous cell carcinoma that cannot be radically treated by surgery, radiotherapy or chemoradiotherapy.
No prior systemic anti-cancer therapy for recurrent/metastatic disease.
According to RECIST v1.1 criteria, the patient must have at least one measurable lesion.
Has any malignancy <5 years prior to study entry.
Known to have brain or meningeal metastasis.
Known to have autoimmune disease.
Received live vaccinations 4 weeks before randomization or during the study period.